Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Emerg Microbes Infect. 2017 Oct 11;6(10):e89. doi: 10.1038/emi.2017.79.
The Zika virus (ZIKV), a flavivirus transmitted by Aedes mosquitoes, has emerged as a global public health concern. Pre-existing cross-reactive antibodies against other flaviviruses could modulate immune responses to ZIKV infection by antibody-dependent enhancement, highlighting the importance of understanding the immunogenicity of the ZIKV envelope protein. In this study, we identified a panel of human monoclonal antibodies (mAbs) that target domain III (DIII) of the ZIKV envelope protein from a very large phage-display naive antibody library. These germline-like antibodies, sharing 98%-100% hoLogy with their corresponding germline IGHV genes, bound ZIKV DIII specifically with high affinities. One mAb, m301, broadly neutralized the currently circulating ZIKV strains and showed a synergistic effect with another mAb, m302, in neutralizing ZIKV in vitro and in a mouse model of ZIKV infection. Interestingly, epitope mapping and competitive binding studies suggest that m301 and m302 bind adjacent regions of the DIII C-C' loop, which represents a recently identified cryptic epitope that is intermittently exposed in an uncharacterized virus conformation. This study extended our understanding of antigenic epitopes of ZIKV antibodies and has direct implications for the design of ZIKV vaccines.
寨卡病毒(ZIKV)是一种由伊蚊传播的黄病毒,已成为全球公共卫生关注的焦点。针对其他黄病毒的预先存在的交叉反应性抗体可能通过抗体依赖性增强来调节对 ZIKV 感染的免疫反应,这凸显了了解 ZIKV 包膜蛋白免疫原性的重要性。在这项研究中,我们从一个非常大的噬菌体展示原始抗体文库中鉴定出了一组针对 ZIKV 包膜蛋白结构域 III(DIII)的人源单克隆抗体(mAbs)。这些与相应的胚系 IGHV 基因具有 98%-100%同源性的胚系样抗体特异性结合 ZIKV DIII,具有高亲和力。一种 mAb,m301,广泛中和目前流行的 ZIKV 株,并在体外中和 ZIKV 和 ZIKV 感染的小鼠模型中与另一种 mAb,m302,表现出协同作用。有趣的是,表位作图和竞争结合研究表明,m301 和 m302 结合 DIII C-C'环的相邻区域,这代表了一个最近确定的隐匿表位,该表位在一种未表征的病毒构象中间歇性暴露。这项研究扩展了我们对 ZIKV 抗体抗原表位的理解,并直接影响 ZIKV 疫苗的设计。